Department of Ophthalmology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck.
Department of Pharmacy, North Shore University Hospital.
J Glaucoma. 2018 Sep;27(9):e145-e147. doi: 10.1097/IJG.0000000000000995.
We describe a case of bilateral angle closure glaucoma following the infusion of daratumumab, a monoclonal antibody used to treat relapsing multiple myeloma.
This is an interventional case report.
A 59-year-old woman presented with bilateral angle closure glaucoma one day following her first infusion of daratumumab. B-scan echography showed ciliochoroidal effusions in both eyes. Cycloplegia was implemented given the suspicion for drug-induced angle closure, which resulted in prompt deepening of the anterior chambers and normalization of intraocular pressures. The ciliochoroidal effusions resolved 16 days following the cessation of daratumumab.
Daratumumab may be associated with drug-induced secondary angle closure glaucoma.
我们描述了一例在使用达雷妥尤单抗（一种用于治疗复发性多发性骨髓瘤的单克隆抗体）输注后发生的双侧闭角型青光眼。
这是一个介入性病例报告。
一名 59 岁女性在接受达雷妥尤单抗首次输注后一天出现双侧闭角型青光眼。双眼 B 超检查显示睫状体脉络膜渗出。考虑到药物诱导性闭角型青光眼的可能性，给予睫状肌麻痹，结果前房迅速加深，眼内压恢复正常。在停止使用达雷妥尤单抗 16 天后，睫状体脉络膜渗出物消退。
达雷妥尤单抗可能与药物诱导的继发性闭角型青光眼有关。
